J1569 HCPCS code: Injection, immune globulin, (gammagard liquid/gammagard liquid erc), 500 mg
J1569 is the HCPCS Level II code for injection, immune globulin, (gammagard liquid/gammagard liquid erc), 500 mg. In 2024 Medicare paid an average of $35.36 per service for J1569 across 5,992,576 services. Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met. The NCCI unit limit is 400 per day on DME suppliers. Medicare volume rose 35% from 2022 to 2024 (4,434,154 to 5,992,576 services). In 2024, 271 suppliers billed Medicare for J1569 (purchases), serving 1,346 beneficiaries; California, Florida, Massachusetts accounted for 29% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2008-01-01 |
| Last action effective | 2026-07-01 |
Who bills J1569 (2024)
| Measure | Value |
|---|---|
| Suppliers billing rentals | — |
| Suppliers billing purchases | 271 |
| Referring clinicians | 1,030 |
| Medicare beneficiaries | 1,346 |
| States with claims | 48 |
| Share of services in top 3 states (California, Florida, Massachusetts) | 29% |
| Year | Suppliers | Beneficiaries |
|---|---|---|
| 2022 | 261 | 1,353 |
| 2023 | 248 | 1,337 |
| 2024 | 271 | 1,346 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J1569, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 4,434,154 | 7,492 | $44.32 | $35.38 |
| 2023 | 5,636,921 | 8,914 | $44.59 | $35.49 |
| 2024 | 5,992,576 | 9,296 | $44.43 | $35.36 |
States with the most J1569 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 1,159,753 | $35.52 |
| California | 509,014 | $35.32 |
| Texas | 486,830 | $35.32 |
| Illinois | 436,351 | $35.46 |
| Tennessee | 267,823 | $35.35 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| DME suppliers | 400 | Clinical: Data |
| outpatient hospital claims | 400 | Clinical: Data |
| practitioner claims | 400 | Clinical: Data |
Medicare policy articles for this code
- A52507: External Infusion Pumps - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC)) — mentions this code in its coding guidance
- A52509: Intravenous Immune Globulin - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC)) — mentions this code in its coding guidance
- A56718: Billing and Coding: Intravenous Immunoglobulin (IVIG) (Palmetto GBA (MAC - Part A, MAC - Part B))
- A56779: Billing and Coding: Intravenous Immune Globulin (CGS Administrators, LLC (MAC - Part A, MAC - Part B))
- A56786: Billing and Coding: Immune Globulin (Novitas Solutions, Inc. (MAC - Part A, MAC - Part B))
- A57160: Billing and Coding: Immune Thrombocytopenia (ITP) Therapy (CGS Administrators, LLC (MAC - Part A, MAC - Part B))
- A57187: Billing and Coding: Immune Globulin Intravenous (IVIg) (Noridian Healthcare Solutions, LLC (MAC - Part A, MAC - Part B))
- A57554: Billing and Coding: Immune Globulins (WPS Insurance Corporation (MAC - Part A, MAC - Part B))
- A57778: Billing and Coding: Immune Globulin (First Coast Service Options, Inc. (MAC - Part A, MAC - Part B))
- A59105: Billing and Coding: Off-Label Use of Intravenous Immune Globulin (IVIG) (Wellpoint Federal (MAC - Part A, MAC - Part B))
Covered diagnoses (1,880 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| D80.0 | Hereditary hypogammaglobulinemia | 9 |
| D80.2 | Selective deficiency of immunoglobulin A [IgA] | 9 |
| D80.3 | Selective deficiency of immunoglobulin G [IgG] subclasses | 9 |
| D80.4 | Selective deficiency of immunoglobulin M [IgM] | 9 |
| D80.5 | Immunodeficiency with increased immunoglobulin M [IgM] | 9 |
| D80.6 | Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia | 9 |
| D80.7 | Transient hypogammaglobulinemia of infancy | 9 |
| D81.0 | Severe combined immunodeficiency [SCID] with reticular dysgenesis | 9 |
| D81.1 | Severe combined immunodeficiency [SCID] with low T- and B-cell numbers | 9 |
| D81.2 | Severe combined immunodeficiency [SCID] with low or normal B-cell numbers | 9 |
Showing 10 of 1,880. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J1569
- July 2026: Descriptor revised (Was: Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg)
- 2008-01-01: J1569 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J1569?
J1569 is the HCPCS Level II code for injection, immune globulin, (gammagard liquid/gammagard liquid erc), 500 mg. Short descriptor: "Gammagard liquid/erc inj".
How much does Medicare pay for J1569?
In 2024, the average Medicare payment was $35.36 per service (average allowed $44.43).
Does Medicare cover J1569?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
Which diagnoses support coverage for J1569?
Medicare policy articles that cite J1569 list 1,880 covered ICD-10-CM diagnosis codes across 10 articles. The most cited include D80.0 (Hereditary hypogammaglobulinemia), D80.2 (Selective deficiency of immunoglobulin A [IgA]), D80.3 (Selective deficiency of immunoglobulin G [IgG] subclasses). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J1569 can be billed per day?
400 on DME suppliers; 400 on outpatient hospital claims; 400 on practitioner claims (NCCI medically unlikely edits).
Related J15 codes
- J1551 — Injection, immune globulin (cutaquig), 100 mg
- J1552 — Injection, immune globulin (alyglo), 500 mg
- J1553 — Injection, immune globulin (yimmugo), 100 mg
- J1554 — Injection, immune globulin (asceniv), 500 mg
- J1555 — Injection, immune globulin (cuvitru), 100 mg
- J1556 — Injection, immune globulin (bivigam), 500 mg
- J1557 — Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg
- J1558 — Injection, immune globulin (xembify), 100 mg
- J1559 — Injection, immune globulin (hizentra), 100 mg
- J1560 — Injection, gamma globulin, intramuscular, over 10 cc
- J1561 — Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg
- J1562 — Injection, immune globulin (vivaglobin), 100 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J1569
- Watch J1569 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1569
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.